Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers11101528
Title: | Inhibition of TFF3 enhances sensitivity—and overcomes acquired resistance—to doxorubicin in estrogen receptor-positive mammary carcinoma | Authors: | Poh, H.M. Chiou, Y.S. Chong, Q.Y. Chen, R.-M. Rangappa, K.S. Ma, L. Zhu, T. Kumar, A.P. Pandey, V. Basappa Lee, S.-C. Lobie, P.E. |
Keywords: | Acquired resistance Apoptosis Dose-dependent toxicity Doxorubicin Mammary carcinoma PI3K/AKT Trefoil factor 3 (TFF3) |
Issue Date: | 2019 | Publisher: | MDPI AG | Citation: | Poh, H.M., Chiou, Y.S., Chong, Q.Y., Chen, R.-M., Rangappa, K.S., Ma, L., Zhu, T., Kumar, A.P., Pandey, V., Basappa, Lee, S.-C., Lobie, P.E. (2019). Inhibition of TFF3 enhances sensitivity—and overcomes acquired resistance—to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers 11 (10) : 1528. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers11101528 | Rights: | Attribution 4.0 International | Abstract: | Dose-dependent toxicity and acquired resistance are two major challenges limiting the efficacious treatment of mammary carcinoma (MC) with doxorubicin. Herein, we investigated the function of Trefoil Factor 3 (TFF3) in the sensitivity and acquired resistance of estrogen receptor positive (ER+) MC cells to doxorubicin. Doxorubicin treatment of ER+MC cells increased TFF3 expression. The depletion of TFF3 by siRNA or inhibition with a small molecule TFF3 inhibitor (AMPC) synergistically enhanced the efficacy of doxorubicin in ER+MC through the suppression of doxorubicin-induced AKT activation and enhancement of doxorubicin-induced apoptosis. Elevated expression of TFF3 and increased activation of AKT were also observed using a model of acquired doxorubicin resistance in ER+MC cells. AMPC partially re-sensitized the doxorubicin resistant cells to doxorubicin-induced apoptosis. Indeed, doxorubicin resistant ER + MC cells exhibited increased sensitivity to AMPC as a single agent compared to doxorubicin sensitive cells. In vivo, AMPC attenuated growth of doxorubicin sensitive ER+MC xenografts whereas it produced regression of xenografts generated by doxorubicin resistant ER+MC cells. Hence, TFF3 inhibition may improve the efficacy and reduce required doses of doxorubicin in ER+MC. Moreover, inhibition of TFF3 may also be an effective therapeutic strategy to eradicate doxorubicin resistant ER+MC. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. | Source Title: | Cancers | URI: | https://scholarbank.nus.edu.sg/handle/10635/209544 | ISSN: | 2072-6694 | DOI: | 10.3390/cancers11101528 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_cancers11101528.pdf | 8.75 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License